Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report
Real-time Estimate Cboe BZX  -  01:50 2022-09-27 pm EDT
18.25 USD   +3.78%
06:47aStifel Adjusts Price Target on Deciphera Pharmaceuticals to $18 From $11, Reiterates Hold Rating
MT
09/12Piper Sandler Raises Deciphera Pharmaceuticals Price Target to $18 From $13, Maintains Neutral Rating
MT
09/12SVB Securities Adjusts Deciphera Pharmaceuticals' Price Target to $25 from $21, Maintains Outperform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Deciphera Pharmaceuticals : Announces Second Quarter 2022 Financial Results - Form 8-K

08/04/2022 | 07:17am EDT

Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results

- Second Quarter 2022 Total Revenue of $32.5 Million; QINLOCK® Net Product Revenue Increases 43% to $31.5 Million Compared to Second Quarter 2021 -

- Phase 1 Single Agent Dose Escalation Data for DCC-3116 Selected for Oral Presentation as a Proffered Paper at the ESMO Congress 2022 in September -

- Updated Phase 1/2 Results for Study of Vimseltinib in TGCT Patients Selected for Poster Presentation at the ESMO Congress 2022; Continued Patient Enrollment in the Pivotal Phase 3 MOTION Study -

- Nomination of New Development Candidate from Pan-RAF Research Program Expected by Fourth Quarter 2022 -

WALTHAM, Mass.-(BUSINESS WIRE)-August 4, 2022-Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the second quarter ended June 30, 2022, and provided a corporate update.

"We delivered strong commercial performance in the second quarter with QINLOCK®, and we advanced our portfolio of product candidates with best-in-class potential," said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals. "Germany recently awarded a 'major additional benefit' rating for QINLOCK in its indication in advanced GIST, which is the first time an orphan oncology treatment has received this rating for its lead indication since the introduction of the German benefit assessment of medicinal products over 10 years ago. This, along with a strong commercial launch in Germany and a successful post-approval paid access program in France, demonstrate the potential for QINLOCK to transform how GIST is treated around the world."

Mr. Hoerter continued, "We are also excited that the initial data from the Phase 1 study of DCC-3116, our potential first-in-class autophagy inhibitor, has been selected for an oral presentation at ESMO next month. Additionally, enrollment in the pivotal Phase 3 MOTION study of vimseltinib for the treatment of TGCT is on track and updated results from the Phase 1/2 study will be presented at ESMO next month, and finally, we expect to nominate the development candidate from our pan-RAF research program by the fourth quarter."

Second Quarter 2022 Highlights and Upcoming Milestones

QINLOCK (ripretinib)

Recorded $31.5 million in QINLOCK net product revenue in the second quarter of 2022, including $23.7 million in U.S. net product revenue and $7.8 million in international net product revenue, an increase of 43% from net product revenue of $22.0 million in the second quarter of 2021.

Received a "major additional benefit" rating from Germany's Federal Joint Committee (G-BA). QINLOCK is the first orphan oncology treatment in Germany to receive this rating for its lead indication and the only GIST treatment awarded with this recognition.

Vimseltinib

Continued patient enrollment in the pivotal Phase 3 MOTION study of vimseltinib for the treatment of TGCT. MOTION is a two-part, randomized, double-blind, placebo-controlled study of vimseltinib to assess the efficacy and safety in patients with TGCT who are not amenable to surgery. The primary endpoint of the study is objective response rate at week 25 as measured by RECIST v1.1 by blinded independent radiologic review.

Expects to present updated results from the ongoing Phase 1/2 study in TGCT patients in a poster presentation at the ESMO Congress 2022 in September.

DCC-3116

Expects to present data in an oral presentation as a Proffered Paper at the ESMO Congress 2022 from the single agent dose escalation portion of the Phase 1 study of DCC-3116 in patients with advanced or metastatic tumors with a mutant RAS or RAF gene.

Expects to initiate three Phase 1b study combination dose escalation cohorts in the second half of 2022:

In combination with trametinib, a Food and Drug Administration (FDA)-approved MEK inhibitor, in patients with advanced or metastatic solid tumors with RAS, NF1, or RAF mutations.

In combination with binimetinib, an FDA-approved MEK inhibitor, in patients with advanced or metastatic solid tumors with RAS, NF1, or RAF mutations.

In combination with sotorasib, an FDA- approved KRASG12C inhibitor, in patients with advanced or metastatic solid tumors with KRASG12C mutations.

Proprietary Drug Discovery Platform

Expects to nominate a development candidate by the fourth quarter of 2022 from the pan-RAF research program discovered using the Company's novel switch-control kinase inhibitor platform.

Corporate Updates

Appointed Kelley Dealhoy as Senior Vice President and Chief Business Officer to develop and lead the Company's business development efforts and corporate strategy initiatives. Ms. Dealhoy brings 20 years of life science leadership experience to the role and joined Deciphera from Novartis, where she most recently served as Vice President of Business Development for the Oncology Division.

Published the 2021 Environmental, Social, and Governance (ESG) Report, highlighting our current practices and initiatives in several important ESG-related areas as of the 2021 fiscal year.

Second Quarter 2022 Financial Results

Revenue: Total revenue for the second quarter of 2022 was $32.5 million, which includes $31.5 million of net product revenue of QINLOCK and $1.0 million of collaboration revenue compared to $23.6 million of total revenue, including $22.0 million of net product revenue of QINLOCK and $1.5 million of collaboration revenue, for the same period in 2021.

Cost of Sales: Cost of sales were $1.8 million in the second quarter of 2022 compared to $1.3 million in the same period in 2021. Cost of sales for newly launched products will not include the full cost of manufacturing until the initial pre-launch inventory is depleted, and additional inventory is manufactured and sold. The Company expects to continue to sell zero cost inventories of QINLOCK in the U.S. through 2022.

R&D Expenses: Research and development expenses for the second quarter of 2022 were $44.9 million, compared to $60.0 million for the same period in 2021. The decrease was primarily due to lower clinical trial costs related to QINLOCK, including INTRIGUE, our Phase 3 study for the treatment of second-line GIST for which top-line results were announced in November 2021, and the discontinuation of our rebastinib program following the corporate restructuring implemented in the fourth quarter of 2021, partially offset by an increase in clinical trial costs related to our Phase 1 study of DCC-3116 and preclinical costs. Non-cash, stock-based compensation was $5.4 million and $5.6 million for the second quarters of 2022 and 2021, respectively.

SG&A Expenses: Selling, general, and administrative expenses for the first quarter of 2022 were $29.6 million, compared to $32.8 million for the same period in 2021. The decrease was primarily due to a decrease in professional and consultant fees. Non-cash, stock-based compensation was $7.6 million and $6.8 million for the second quarters of 2022 and 2021, respectively.

Net Loss: For the second quarter of 2022, Deciphera reported a net loss of $43.1 million, or $0.60 per share, compared with a net loss of $70.4 million, or $1.21 per share, for the same period in 2021.

Cash Position: As of June 30, 2022, cash, cash equivalents, and marketable securities were $393.1 million, compared to $275.4 million as of March 31, 2022. In April 2022, the Company completed an underwritten public offering that resulted in aggregate net proceeds of $163.4 million. Based on its current operating plans, Deciphera expects its current cash, cash equivalents, and marketable securities together with anticipated product, royalty, and supply revenues, but excluding any potential future milestone payments under its collaboration or license agreements, will enable the Company to fund its operating and capital expenditures into 2025.

Conference Call and Webcast

Deciphera will host a conference call and webcast to discuss this announcement today, August 4, 2022, at 8:00 AM ET. The conference call may be accessed via this link: https://register.vevent.com/register/BI14cfe386c5004efcba5c94f8783e2435. A live webcast of the conference call will be available in the "Events and Presentations" page in the "Investors" section of the Company's website at https://investors.deciphera.com/events-presentations. A replay will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera's switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, our expectations and timing regarding the potential of QINLOCK to transform how GIST is treated around the world, enrollment in the pivotal Phase 3 MOTION study of vimseltinib in TGCT patients, the potential for our pre-clinical and/or clinical stage pipeline assets to be first-in-class and/or best-in-class treatments, presenting updated vimseltinib data from our Phase 1/2 study in TGCT patients at ESMO 2022, presenting initial data from the single agent dose escalation phase of the Phase 1 study of DCC-3116 at ESMO 2022, initiation of three combination dose escalation cohorts in the Phase 1 study of DCC-3116, nominating a development candidate for our pan-RAF research program, and cash guidance. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "seek," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the severity and duration of the impact of COVID-19 on our business and operations, our ability to successfully demonstrate the efficacy and safety of our drug or drug candidates, the preclinical or clinical results for our product candidates, which may not support further development of such product candidates, comments, feedback and actions of regulatory agencies, our ability to commercialize QINLOCK and execute on our marketing plans for any drugs or indications that may be approved in the future, the inherent uncertainty in estimates of patient populations, competition from other products, our ability to obtain and maintain reimbursement for any approved product and the extent to which patient assistance programs are utilized and other risks identified in our Securities and Exchange Commission (SEC) filings, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 , and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Deciphera, the Deciphera logo, QINLOCK, and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC.

Deciphera Pharmaceuticals, Inc.

Consolidated Balance Sheets

(Unaudited, in thousands, except share and per share amounts)

June 30, 2022 December 31,
2021

Assets

Current assets:

Cash and cash equivalents

$ 109,698 $ 87,063

Short-term marketable securities

274,149 198,571

Accounts receivable, net

25,851 20,595

Inventory

20,889 14,125

Prepaid expenses and other current assets

17,944 18,660

Total current assets

448,531 339,014

Long-term marketable securities

9,208 41,950

Long-term investments-restricted and other long-term assets

3,269 3,110

Property and equipment, net

7,353 8,610

Operating lease assets

38,676 36,800

Total assets

$ 507,037 $ 429,484

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable

$ 16,229 $ 13,130

Accrued expenses and other current liabilities

55,214 80,773

Operating lease liabilities

3,102 2,870

Total current liabilities

74,545 96,773

Operating lease liabilities, net of current portion

27,481 27,991

Total liabilities

102,026 124,764

Commitments and contingencies

Stockholders' equity:

Preferred stock, $0.01 par value per share; 5,000,000 shares authorized; no shares issued or outstanding

- -

Common stock, $0.01 par value per share; 125,000,000 shares authorized; 66,815,511 shares and 58,549,644 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively

668 585

Additional paid-in capital

1,549,996 1,358,516

Accumulated other comprehensive income (loss)

(1,268 ) 51

Accumulated deficit

(1,144,385 ) (1,054,432 )

Total stockholders' equity

405,011 304,720

Total liabilities and stockholders' equity

$ 507,037 $ 429,484

Deciphera Pharmaceuticals, Inc.

Consolidated Statements of Operations

(Unaudited, in thousands, except share and per share amounts)

Three Months Ended June 30, Six Months Ended June 30,
2022 2021 2022 2021

Revenues:

Product revenues, net

$ 31,497 $ 22,048 $ 60,306 $ 42,010

Collaboration revenues

997 1,525 1,411 6,719

Total revenues

32,494 23,573 61,717 48,729

Cost and operating expenses:

Cost of sales

1,799 1,275 2,181 1,497

Research and development

44,858 59,984 92,270 115,665

Selling, general, and administrative

29,625 32,828 57,946 63,575

Total cost and operating expenses

76,282 94,087 152,397 180,737

Loss from operations

(43,788 ) (70,514 ) (90,680 ) (132,008 )

Other income (expense):

Interest and other income, net

727 81 727 277

Total other income (expense), net

727 81 727 277

Net loss

$ (43,061 ) $ (70,433 ) $ (89,953 ) $ (131,731 )

Net loss per share-basic and diluted

$ (0.60 ) $ (1.21 ) $ (1.31 ) $ (2.28 )

Weighted average common shares outstanding-basic and diluted

72,133,428 57,987,095 68,441,998 57,867,795

Contacts

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902

Media:

David Rosen Argot Partners

david.rosen@argotpartners.com

212-600-1902

Disclaimer

Deciphera Pharmaceuticals Inc. published this content on 04 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2022 11:14:27 UTC.


© Publicnow 2022
All news about DECIPHERA PHARMACEUTICALS, INC.
06:47aStifel Adjusts Price Target on Deciphera Pharmaceuticals to $18 From $11, Reiterates Ho..
MT
09/12Piper Sandler Raises Deciphera Pharmaceuticals Price Target to $18 From $13, Maintains ..
MT
09/12SVB Securities Adjusts Deciphera Pharmaceuticals' Price Target to $25 from $21, Maintai..
MT
09/12HC Wainwright Adjusts Deciphera Pharmaceuticals' Price Target to $25 from $20, Reiterat..
MT
09/12Deciphera Pharmaceuticals, Inc. : Regulation FD Disclosure, Financial Statements and Exhib..
AQ
09/11Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT..
BU
09/11Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT..
CI
09/10Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation D..
BU
09/10Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation D..
CI
09/01Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Le..
BU
More news
Analyst Recommendations on DECIPHERA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 130 M - -
Net income 2022 -178 M - -
Net cash 2022 190 M - -
P/E ratio 2022 -6,94x
Yield 2022 -
Capitalization 1 175 M 1 175 M -
EV / Sales 2022 7,59x
EV / Sales 2023 6,24x
Nbr of Employees 280
Free-Float 72,4%
Chart DECIPHERA PHARMACEUTICALS, INC.
Duration : Period :
Deciphera Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DECIPHERA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 17,58 $
Average target price 18,78 $
Spread / Average Target 6,81%
EPS Revisions
Managers and Directors
Steven L. Hoerter President & Chief Executive Officer
Thomas P. Kelly Chief Financial Officer, Treasurer & Executive VP
James A. Bristol Chairman
Daniel L. Flynn President, Chief Executive Officer & Director
Stephen B. Ruddy Chief Technical Officer & SVP
Sector and Competitors
1st jan.Capi. (M$)
DECIPHERA PHARMACEUTICALS, INC.79.94%1 175
GILEAD SCIENCES, INC.-14.14%78 135
REGENERON PHARMACEUTICALS, INC.8.64%73 350
VERTEX PHARMACEUTICALS26.04%70 983
BIONTECH SE-50.48%31 021
WUXI APPTEC CO., LTD.-40.57%28 544